UK charity plugs drug R&D gap
Cancer Research Technology, a British cancer charity, is to fund clinical trials of a drug owned by GlaxoSmithKline (GSK), in a groundbreaking programme to develop promising experimental medicines that are neglected due to limited corporate funding.
Cancer Research Technology, a British cancer charity, is to fund clinical trials of a drug owned by GlaxoSmithKline (GSK), in a groundbreaking programme to develop promising experimental medicines that are neglected due to limited corporate funding.
The charity will shortly begin tests in patients of GSK's 1070916A an aurora kinase inhibitor. If the drug is successfully launched it will retain a share of the profits.
"GSK has got a large number of molecules in its pipeline and many merit investogation. But it can's take them all into the clinic at the same time so a numner end up sitting on the shelf," remarked Cancer Research's licensing manager, Ian Walker.
The charity will fund early and mid-stage testing in humans before offering GSk the opportunity to finance the more expensive late-stage clinical trials. If GSK decline, it may offer the rights to another company instead.
Terms of the agreement have not been disclosed.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
